Skip to main content
NIH funding notice RFA-NS-21-010

HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)

Closed on November 2, 2023.

Posted
September 16, 2020
Close date
November 2, 2023
Activity codes
UG3, UH3
Institutes taking part
NINDS, NEI, NIAAA, NIAMS, NICHD, NIDCR, NIDDK, NIDA, NCCIH, NHLBI, ORWH

The notices it replaced

1 notice since 2018, oldest first, each with its awards since FY2014.

  1. Posted 2018RFA-NS-19-0104 awards
  2. Posted 2020RFA-NS-21-010This notice, closed · 12 awards

Replaced by RFA-NS-24-019.

Who won it before

Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.

Past awards
16
16 new
Median first-year cost
$1,895,271
$30,833,325 in all
Institutions
16
16 contact PIs

Awards by fiscal year

Fiscal years 2014 to 2026.

Most frequent institutions

  1. CENTREXION THERAPEUTICS CORPORATION1
  2. CLEVELAND CLINIC LERNER COM-CWRU1
  3. FZATA, INC.1
  4. HILLHURST BIOPHARMACEUTICALS, INC.1
  5. IHP THERAPEUTICS, INC.1

and 11 other institutions

Most frequent study sections

  1. Special Emphasis Panel (ZNS1 SRB-G (37))3
  2. Special Emphasis Panel (ZNS1 SRB-G (45))2
  3. Special Emphasis Panel (ZNS1 SRB-G (51))2
  4. Special Emphasis Panel (ZNS1 SRB-G (55))2
  5. Special Emphasis Panel (ZNS1 SRB-H (05))2

and 4 other study sections

16 awards under RFA-NS-21-010 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
FY2024A novel oral immunotherapy for chronic visceral pain of irritable bowel syndrome1UG3NS135350-01A1Feng, HanpingWei, FengYang, ZhiyongFZATA, INC., MDFirst-year cost $2,091,549Study section ZNS1
FY2023Peripherally-restricted non-addictive cannabinoids for cancer pain treatment1UG3NS128148-01A1Cahill, Catherine MSchmidt, Brian LSpigelman, IgorSpokoyny, Alexander MichaelWhitelegge, Julian PUNIVERSITY OF CALIFORNIA LOS ANGELES, CAFirst-year cost $3,174,343Study section ZNS1
FY2023A novel glycan-based selectin and complement inhibitor for at-home disease-modifying rescue of pain crisis in sickle cell disease1UG3NS134781-01John Paderi, John Paderi John PaderiIHP THERAPEUTICS, INC., CAFirst-year cost $2,589,070Study section ZNS1
FY2023Development of positive TMEM97 modulators for treating neuropathic pain1UG3NS131304-01Martin, StephenNUVONURO INC, TXFirst-year cost $1,352,240Study section ZNS1
FY2023Anesthetic-Eluting Contact Lens for Corneal Pain1UG3NS131518-01Ciolino, Joseph B.SCHEPENS EYE RESEARCH INSTITUTE, MAFirst-year cost $1,120,889Study section ZNS1
FY2022Allosteric Targeting of Cannabinoid CB1 Receptor to Develop Non-Addictive Small Molecule Analgesics1UG3NS128439-01Lu, DaiSelley, Dana ETao, FengTEXAS A&M UNIVERSITY HEALTH SCIENCE CTR, TXFirst-year cost $2,903,097Study section ZNS1
FY2022Development of Pathology-activated Drugs for Treatment of Neuropathic Pain1UG3NS127251-01A1Abell, AndrewGrace, Peter MUNIVERSITY OF TX MD ANDERSON CAN CTR, TXFirst-year cost $2,408,109Study section ZNS1
FY2022Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease1UG3NS127943-01Belcher, John DGomperts, EdwardSimone, DonaldHILLHURST BIOPHARMACEUTICALS, INC., CAFirst-year cost $2,111,258Study section ZNS1
FY2022A first in class, mechanism-guided, cell-based therapy for complex regional pain syndrome1UG3NS127258-01A1Cheng, JianguoCLEVELAND CLINIC LERNER COM-CWRU, OHFirst-year cost $2,033,135Study section ZNS1
FY2021Novel, Non-Opioid, Non-Addictive Intrathecal Therapy for the Treatment of Chronic Pain1UG3NS123965-01Campbell, James NCENTREXION THERAPEUTICS CORPORATION, MAFirst-year cost $2,050,367Study section ZNS1
FY2021Disease Modifying Analgesia with CA8 Gene Therapy1UG3NS123964-01Levitt, Roy C.UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, FLFirst-year cost $1,516,241Study section ZNS1
FY2021Development of a CCKBR-targeting scFv as Therapy for Chronic Pain Patients1UG3NS123958-01Alles, Sascha RWestlund-High, Karin N.UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NMFirst-year cost $999,105Study section ZNS1
FY2019Novel HCN1-selective small molecule inhibitors for the treatment of neuropathic pain1UG3NS114947-01 · under RFA-NS-19-010Goldstein, Peter AWEILL MEDICAL COLL OF CORNELL UNIV, NYFirst-year cost $1,757,406Study section ZNS1
FY2019Novel mGlu5 negative allosteric modulators as first-in-class non-addictive analgesic therapeutics1UG3NS116218-01 · under RFA-NS-19-010Conn, P JeffreyGereau, Robert WLindsley, CraigRook, Jerri MichelleVANDERBILT UNIVERSITY, TNFirst-year cost $1,585,635Study section ZNS1
FY2019Development of MRGPRX1 positive allosteric modulators as non-addictive therapies for neuropathic pain1UG3NS115718-01 · under RFA-NS-19-010Tsukamoto, TakashiJOHNS HOPKINS UNIVERSITY, MDFirst-year cost $1,583,144Study section ZNS1
FY2019Optimization of non-addictive biologics to target sodium channels involved in pain signaling1UG3NS114956-01 · under RFA-NS-19-010Wulff, HeikeYarov-Yarovoy, Vladimir MUNIVERSITY OF CALIFORNIA AT DAVIS, CAFirst-year cost $1,557,737Study section ZNS1
Newest fiscal year first, then first-year cost.

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-16-0.3.5. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for departments

Open NIH notices that fit your faculty

See which open NIH funding notices fit each faculty member's CV, why each fits, and who won before.